相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Future of Somatostatin Receptor Ligands in Acromegaly
Monica R. Gadelha et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Innovative therapeutics in acromegaly
Leandro Kasuki et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2022)
Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR
Peter Wolf et al.
ENDOCRINE CONNECTIONS (2022)
Machine Learning-based Prediction Model for Treatment of Acromegaly With First-generation Somatostatin Receptor Ligands
Luiz Eduardo Wildemberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2021)
Long-term safety and efficacy of long-acting pasireotide in acromegaly
Amit Akirov et al.
ENDOCRINE (2021)
Pasireotide for acromegaly: long- term outcomes from an extension to the Phase III PAOLA study
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly
Eva C Coopmans et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Multidisciplinary management of acromegaly: A consensus
Andrea Giustina et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2020)
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly
Monica R. Gadelha et al.
ENDOCRINE CONNECTIONS (2020)
Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update
Monica R. Gadelha et al.
ENDOCRINE REVIEWS (2019)
National acromegaly registries
Luigi Maione et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2019)
Potential antitumour activity of pasireotide on pituitary tumours in acromegaly
Eva C. Coopmans et al.
LANCET DIABETES & ENDOCRINOLOGY (2019)
Personalized medicine in the treatment of acromegaly
Leandro Kasuki et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2018)
A Consensus Statement on acromegaly therapeutic outcomes
Shlomo Melmed et al.
NATURE REVIEWS ENDOCRINOLOGY (2018)
Predictors of surgical outcome and early criteria of remission in acromegaly
Ximene Antunes et al.
ENDOCRINE (2018)
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study
Marcello D. Bronstein et al.
BMC ENDOCRINE DISORDERS (2016)
Predictors of Quality of Life in Acromegaly: No Consensus on Biochemical Parameters
Victor J. Geraedts et al.
FRONTIERS IN ENDOCRINOLOGY (2016)
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study
Michael Sheppard et al.
PITUITARY (2015)
Could different treatment approaches in acromegaly influence life expectancy? A comparative study between Bulgaria and Campania (Italy)
Annamaria Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2014)
Acromegaly: An Endocrine Society Clinical Practice Guideline
Laurence Katznelson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
A. Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2014)
Effects of Subcutaneous Pasireotide on Cardiac Repolarization in Healthy Volunteers: A Single-Center, Phase I, Randomized, Four-Way Crossover Study
Astrid Breitschaft et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
EXPERT CONSENSUS DOCUMENT A consensus on the medical treatment of acromegaly
Andrea Giustina et al.
NATURE REVIEWS ENDOCRINOLOGY (2014)
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial
Monica R. Gadelha et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Hyperglycemia Associated With Pasireotide: Results From a Mechanistic Study in Healthy Volunteers
Robert R. Henry et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Pathology of pituitary tumors
N Sanno et al.
NEUROSURGERY CLINICS OF NORTH AMERICA (2003)
SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
C Bruns et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2002)
分享论文
